LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

uniQure NV

Fermé

17.2 3.12

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.68

Max

17.47

Chiffres clés

By Trading Economics

Revenu

30M

-44M

Ventes

-3.7M

1.6M

BPA

-0.728

Marge bénéficiaire

-2,784.748

Employés

209

EBITDA

14M

-39M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+140.82% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

73M

793M

Ouverture précédente

14.08

Clôture précédente

17.2

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

uniQure NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 déc. 2024, 15:18 UTC

Principaux Mouvements du Marché

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Comparaison

Variation de prix

uniQure NV prévision

Objectif de Prix

By TipRanks

140.82% hausse

Prévisions sur 12 Mois

Moyen 40 USD  140.82%

Haut 70 USD

Bas 24 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

8

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

10.05 / 14.75Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.